点击订阅北美候鸟长辈关注计划
【北美候鸟‧专家说】系列公益讲座
第3期 美国律师详解: 父母来美久居/移民指南》
第2期 《美国医生详述:在美生活须知的非处方药&常见症状应对》
第1期 美国律师解析:滞美期间身份延期及绿卡身份保持
-----
讲座内容回顾预告(即将发布文字版):
第4期  《美国医生:全面解析美国新冠疫苗》
第5期  《美国律师:疫情期间学生签工作签如何延期》
【北美候鸟‧专家说】系列公益讲座第6期
正在直播:《解读中美新冠疫苗》
演讲嘉宾:张洪涛, 研究副教授,Ph.D. 
宾夕法尼亚大学医学院病理及实验医药系
1999年取得美国宾夕法尼亚大学药理学博士学位,并于该校病理系完成博士后研究。2007年起任职于宾夕法尼亚大学医学院病理及实验医药系。
本期主题:
1. 核酸:阳性、抗体阳性的区别?抗原检测及"双阴性"是什么?作用是什么?能够完全挡住感染者回国吗?
2. 疫苗:哪种疫苗较好?如何决策是否打疫苗(年龄/感染风险);注射疫苗后的注意事项(不良反应,不能放弃防护);疫苗保护的有效期;能否应对病毒的变异?
3. 中美疫苗对比;为什么美国疫苗没有限制年龄,中国疫苗限制多;中美之间疫苗的相互认可和接受情况
4. 没有疫苗时,大家如何防护?如果疫苗没有防护住,有什么好的治疗方法?
嘉宾介绍:
张洪涛, 研究副教授,Ph.D.

研究背景:
1999年在美国宾夕法尼亚大学取得药理学博士学位,并于该校病理系完成博士后研究,自2007年起任职于宾夕法尼亚大学医学院病理及实验医药系研究助理教授。主要研究方向为靶向药物在癌症及免疫疾病中的治疗、重组蛋白药物对癌症的靶向免疫治疗、以及巨噬细胞在免疫和肿瘤中的功能。具体侧重的靶向分子为ErbB家族受体(包括表皮生长因子受体EGFR, HER2, 及HER3)和TNF受体,建立了一系列融合蛋白的技术平台,成功获得了抗癌效果优于抗体的创新靶向免疫治疗蛋白。所做研究获得美国NIH、美国国会指导医学研究项目等资助,是一序列项目的主要负责人(PI)和协同主要负责人(co-PI)。在Nature Medicine, Nature Biotechnology, 等权威科学杂志上发表过80多篇论文,是12个已批准专利和一系列待批专利的发明人。有参与美国早期生物科技公司创建的经验,并担任过一些公司的科学顾问。任中美制药专业人士联合会会员,美国抗体协会会员。曾参加美国乳腺癌和前列腺癌的研究基金审评。受聘为河北医科大学第四医院客座教授。
科普活动:
科普著作:
1. 《吃什么呢?——舌尖上的思考》(漓江出版社,2014)
2. 《如果舌尖能思考》(清华出版社, 2017)
微信公众号主笔:“一节生姜”
今日头条号:“一节生姜”
搜狐号:“一节生姜”
澎湃号:“一节生姜”
其他聘约:
·  广东省药品监督管理局科普宣传专家
·  腾讯较真签约作者
·  凤凰网肿瘤观察局签约作者
·  春雨医生特约作者
· 丁香园特约专家
· 腾讯医典特约专家
· 凤凰卫视“全球连线”评论员
https://youtu.be/9oygje16HOY
https://youtu.be/scDrSdqn8Wg
· 中国环球电视网(CGTN)评论员
https://www.youtube.com/watch?v=IFsITmRj_Iw
https://newsus.cgtn.com/news/2019-12-18/Hongtao-Zhang-discusses-Chinese-medical-advancements-Mvy9WFs9La/index.html
媒体采访:
  • 时代周报:
专家提示:新冠病毒可由粪便传播,公共卫生间是高危区域!
  • 人民日报健康客户端:
美国新冠肺炎重症病死率高达67%?专家这样看
1个月美国确诊病例涨2000倍,未来两周或可达峰值
最快18个月面世!为何WHO有信心为新冠疫苗按下快进键?
  • 凤凰名人点对点:
Research Activity:
Dr. Hongtao Zhang is a Research Associate Professor in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania Perelman School of Medicine.  He graduated from the University of Pennsylvania in 1999 with a Ph.D. degree in Pharmacology.  Currently his research focus is receptor- targeted therapies in cancer and immune diseases using antibodies, antibody-like proteins, and small molecules.  One class of focused targets are the ErbB receptors, including EGFR, HER2, and HER3. He has devoted to establish platforms for engineered proteins with antibody-like and better-than-antibody functions. The research projects in Dr. Zhang’s lab are relevant to understanding functions of cytokines in the regulation of immune cells in tumor microenvironments, including the polarization of tumor associated macrophages.  He is also devoted to the identification of serum biomarkers that can help the diagnosis and therapeutic guidance for breast cancer and melanoma.  He has published more than 80 articles in journals including Nature Medicine and Nature Biotechnology.  Dr. Zhang is listed as inventors in 12 approved patents and some other pending patents.  He serves as an editorial board member for several journals.
Promotion of Popular science and Patient Education:
Dr. Zhang has published two non-fiction books (in Chinese) to promote popular science. Over the past several years, he has engaged in patient education by giving talks and writing articles on diseases and treatments, with cancer as one the major focus. His articles are mainly published in Wechat (ID: yjsjusa), which is the most popular social media in Chinese language. Many articles have also been published by other platforms, including 今日头条 (30 million views) and Sohu. He has established networks with several patient education organizations in China.  He also provides expert opinions to many media agencies.
Here are some links to media reports:
·      https://www.youtube.com/watch?v=IFsITmRj_Iw
·      https://newsus.cgtn.com/news/2019-12-18/Hongtao-Zhang-discusses-Chinese-medical-advancements-Mvy9WFs9La/index.html
·      https://youtu.be/9oygje16HOY
继续阅读
阅读原文